I keep saying, and no one is listening, that NDA for Paxalisib vs. DIPG will be applied-for before the NDA for GBM. There's about a $200 million dollar difference to the company, just in the application, and grant or not, of the PRV.
Meanwhile, people keep selling their "artifact" for a dollar now, when it'll be worth 3 dollars in 6 months.
Think ahead.
Expand
